Indian Journal of Pharmacy and Pharmacology
Official Publication of Innovative Education and Scientific Research Foundation
Official Publication of Innovative Education and Scientific Research Foundation
Print ISSN: 2393-9079
Online ISSN: 2393-9087
CODEN : IJPPTK
Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...Original Article
Author Details :
Volume : 10, Issue : 4, Year : 2023
Article Page : 281-287
https://doi.org/10.18231/j.ijpp.2023.048
Abstract
Background: Cardiovascular diseases (CVDs) are the major cause of health problems and death worldwide.
Objective: To review the efficacy of Metoprolol and Apixaban in the treatment of cardiovascular diseases by meta-analysis studies.
Materials and Methods: Various databases like PubMed, SciELO, Scopus, Google Scholar, and ResearchGate were used to collect the related studies that were published in English during the years 1980-2013. Only Random Clinical Trials (RCT) were included in this analysis. Risk bias assessment was according to the Cochrane Handbook for Systemic Reviews of the Interventions 6.4. Meta-analysis was done with the help of RevMan 5.4 software.
Results: A total of 10 (one study with different drug concentrations) related articles with 33312 patients were selected for this meta-analysis. In the Metoprolol-treated observation group of patients, the rate of cardiovascular mortality/morbidity [M.H=0.80,95%CI=0.67-0.95, Z=2.5, and P=0.01] was lower and in Apixaban-treated patients [M.H=0.32,95%CI=0.08-1.19, Z=1.7 and P=0.09] the rate of cardiovascular mortality/morbidity were higher and the difference was noted.
Conclusions: It's clear that Apixaban and Metoprolol have a great role in treating cardiovascular diseases. The authors however acknowledge the presence of publication bias and limitations stemming from small sample sizes in some studies, demonstrating a critical and unbiased approach to analysis. Furthermore, it wisely calls for future research endeavors with larger sample sizes, contributing to the ongoing enhancement of treatments for cardiovascular diseases. This balanced and forward-looking analysis consolidates the importance of pharmaceutical interventions in managing cardiovascular diseases.
Keywords: Apixaban, Metoprolol, Cardiovascular disease, Meta-analysis
How to cite : Mavila P, Jamali M C, Efficacy of Metoprolol and Apixaban in the treatment of cardiovascular diseases: A meta-analysis. Indian J Pharm Pharmacol 2023;10(4):281-287
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
